Titre : Immunoglobuline A sécrétoire

Immunoglobuline A sécrétoire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Brain Ischemia
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Immunoglobuline A sécrétoire : Questions médicales les plus fréquentes", "headline": "Immunoglobuline A sécrétoire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Immunoglobuline A sécrétoire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-12", "dateModified": "2025-04-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Immunoglobuline A sécrétoire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Immunoglobuline A", "url": "https://questionsmedicales.fr/mesh/D007070", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline A", "code": { "@type": "MedicalCode", "code": "D007070", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.026" } } }, "about": { "@type": "MedicalCondition", "name": "Immunoglobuline A sécrétoire", "alternateName": "Immunoglobulin A, Secretory", "code": { "@type": "MedicalCode", "code": "D007071", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sonya Kumar Bharathkar", "url": "https://questionsmedicales.fr/author/Sonya%20Kumar%20Bharathkar", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, United States." } }, { "@type": "Person", "name": "Beth M Stadtmueller", "url": "https://questionsmedicales.fr/author/Beth%20M%20Stadtmueller", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, United States." } }, { "@type": "Person", "name": "Georgy A Nevinsky", "url": "https://questionsmedicales.fr/author/Georgy%20A%20Nevinsky", "affiliation": { "@type": "Organization", "name": "Institute of Chemical Biology and Fundamental Medicine, SD of Russian Academy of Sciences, 8 Lavrentiev Ave., Novosibirsk 630090, Russia. Electronic address: nevinsky@niboch.nsc.ru." } }, { "@type": "Person", "name": "Nikit Kumar", "url": "https://questionsmedicales.fr/author/Nikit%20Kumar", "affiliation": { "@type": "Organization", "name": "Department of Structural Biology, Genentech, Inc., South San Francisco, CA, USA 94080." } }, { "@type": "Person", "name": "Christopher P Arthur", "url": "https://questionsmedicales.fr/author/Christopher%20P%20Arthur", "affiliation": { "@type": "Organization", "name": "Department of Structural Biology, Genentech, Inc., South San Francisco, CA, USA 94080." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Generative adversarial network-created brain SPECTs of cerebral ischemia are indistinguishable to scans from real patients.", "datePublished": "2022-11-05", "url": "https://questionsmedicales.fr/article/36335166", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-23325-3" } }, { "@type": "ScholarlyArticle", "name": "Neural cortical organoids from self-assembling human iPSC as a model to investigate neurotoxicity in brain ischemia.", "datePublished": "2023-01-18", "url": "https://questionsmedicales.fr/article/36655331", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/0271678X231152023" } }, { "@type": "ScholarlyArticle", "name": "Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway.", "datePublished": "2022-07-13", "url": "https://questionsmedicales.fr/article/35831547", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10571-022-01251-2" } }, { "@type": "ScholarlyArticle", "name": "LAMP-2A ablation in hippocampal CA1 astrocytes confers cerebroprotection and ameliorates neuronal injury after global brain ischemia.", "datePublished": "2022-09-04", "url": "https://questionsmedicales.fr/article/36059143", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bpa.13114" } }, { "@type": "ScholarlyArticle", "name": "Activated neutrophil-derived exosomes contribute to blood-brain barrier damage and hemorrhagic transformation after cerebral ischemia/reperfusion.", "datePublished": "2023-04-26", "url": "https://questionsmedicales.fr/article/37116559", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.brainres.2023.148374" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Isotypes des immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007132" }, { "@type": "ListItem", "position": 9, "name": "Immunoglobuline A", "item": "https://questionsmedicales.fr/mesh/D007070" }, { "@type": "ListItem", "position": 10, "name": "Immunoglobuline A sécrétoire", "item": "https://questionsmedicales.fr/mesh/D007071" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Immunoglobuline A sécrétoire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Immunoglobuline A sécrétoire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Immunoglobuline A sécrétoire", "description": "Comment mesurer l'IgA sécrétoire ?\nQuels tests diagnostiques sont utilisés ?\nL'IgA sécrétoire est-elle liée à des maladies ?\nQuels symptômes peuvent indiquer un déficit d'IgA ?\nComment évaluer la fonction immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Immunoglobuline A sécrétoire", "description": "Quels symptômes sont associés à un déficit d'IgA ?\nL'IgA sécrétoire affecte-t-elle la digestion ?\nPeut-on avoir des symptômes respiratoires ?\nLes allergies sont-elles liées à l'IgA ?\nComment l'IgA sécrétoire influence-t-elle l'immunité ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Immunoglobuline A sécrétoire", "description": "Comment prévenir les infections respiratoires ?\nL'alimentation influence-t-elle l'IgA ?\nLe stress affecte-t-il l'IgA ?\nLes probiotiques aident-ils l'IgA ?\nLes habitudes de vie influencent-elles l'IgA ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Immunoglobuline A sécrétoire", "description": "Comment traiter un déficit d'IgA ?\nDes suppléments d'IgA existent-ils ?\nLes vaccins sont-ils efficaces ?\nComment prévenir les infections ?\nY a-t-il des traitements alternatifs ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Immunoglobuline A sécrétoire", "description": "Quelles complications peuvent survenir avec un déficit d'IgA ?\nLe déficit d'IgA augmente-t-il le risque d'infections ?\nY a-t-il un lien avec les maladies auto-immunes ?\nLes allergies peuvent-elles s'aggraver ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Immunoglobuline A sécrétoire", "description": "Quels sont les facteurs de risque d'un déficit d'IgA ?\nL'âge influence-t-il l'IgA sécrétoire ?\nLe sexe joue-t-il un rôle ?\nLes infections virales affectent-elles l'IgA ?\nLe mode de vie influence-t-il l'IgA ?", "url": "https://questionsmedicales.fr/mesh/D007071?mesh_terms=Brain+Ischemia&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'IgA sécrétoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IgA sécrétoire est mesurée par des tests d'immunoessai sur des échantillons de mucus ou de salive." } }, { "@type": "Question", "name": "Quels tests diagnostiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sérologiques et des analyses de fluides corporels sont utilisés pour évaluer l'IgA sécrétoire." } }, { "@type": "Question", "name": "L'IgA sécrétoire est-elle liée à des maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'IgA sécrétoire peuvent indiquer des maladies auto-immunes ou des infections." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un déficit d'IgA ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les infections récurrentes des voies respiratoires et digestives peuvent signaler un déficit d'IgA." } }, { "@type": "Question", "name": "Comment évaluer la fonction immunitaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'anticorps spécifiques et des évaluations cliniques sont utilisés pour évaluer la fonction immunitaire." } }, { "@type": "Question", "name": "Quels symptômes sont associés à un déficit d'IgA ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des infections fréquentes, des allergies et des problèmes digestifs." } }, { "@type": "Question", "name": "L'IgA sécrétoire affecte-t-elle la digestion ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un faible niveau d'IgA sécrétoire peut entraîner des troubles digestifs et des infections intestinales." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes respiratoires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un déficit d'IgA sécrétoire peut provoquer des infections respiratoires fréquentes." } }, { "@type": "Question", "name": "Les allergies sont-elles liées à l'IgA ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un déséquilibre d'IgA sécrétoire peut contribuer à des réactions allergiques." } }, { "@type": "Question", "name": "Comment l'IgA sécrétoire influence-t-elle l'immunité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'IgA sécrétoire joue un rôle clé dans la protection des muqueuses contre les agents pathogènes." } }, { "@type": "Question", "name": "Comment prévenir les infections respiratoires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une bonne hygiène, éviter les foules et se faire vacciner sont essentiels." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle l'IgA ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en nutriments peut soutenir la production d'IgA sécrétoire." } }, { "@type": "Question", "name": "Le stress affecte-t-il l'IgA ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut diminuer les niveaux d'IgA sécrétoire et affaiblir l'immunité." } }, { "@type": "Question", "name": "Les probiotiques aident-ils l'IgA ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les probiotiques peuvent aider à maintenir un équilibre immunitaire et soutenir l'IgA." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles l'IgA ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des habitudes de vie saines, comme l'exercice régulier, peuvent améliorer la fonction immunitaire." } }, { "@type": "Question", "name": "Comment traiter un déficit d'IgA ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des antibiotiques pour les infections et des immunoglobulines si nécessaire." } }, { "@type": "Question", "name": "Des suppléments d'IgA existent-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de suppléments d'IgA sécrétoire disponibles sur le marché pour le traitement." } }, { "@type": "Question", "name": "Les vaccins sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccins peuvent être moins efficaces chez les personnes avec un déficit d'IgA sécrétoire." } }, { "@type": "Question", "name": "Comment prévenir les infections ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène, des vaccinations et un suivi médical régulier aident à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des traitements alternatifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements alternatifs comme les probiotiques peuvent aider à renforcer l'immunité." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un déficit d'IgA ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections récurrentes, des allergies et des maladies auto-immunes." } }, { "@type": "Question", "name": "Le déficit d'IgA augmente-t-il le risque d'infections ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec un déficit d'IgA sont plus susceptibles de développer des infections fréquentes." } }, { "@type": "Question", "name": "Y a-t-il un lien avec les maladies auto-immunes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un déficit d'IgA est associé à un risque accru de maladies auto-immunes comme la maladie cœliaque." } }, { "@type": "Question", "name": "Les allergies peuvent-elles s'aggraver ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec un déficit d'IgA peuvent développer des allergies plus sévères." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical régulier et un traitement approprié." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'un déficit d'IgA ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des infections fréquentes et des maladies auto-immunes." } }, { "@type": "Question", "name": "L'âge influence-t-il l'IgA sécrétoire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'IgA sécrétoire peuvent varier avec l'âge, souvent diminuant chez les personnes âgées." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que les hommes peuvent être plus susceptibles d'avoir un déficit d'IgA." } }, { "@type": "Question", "name": "Les infections virales affectent-elles l'IgA ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent temporairement réduire les niveaux d'IgA sécrétoire." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il l'IgA ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain avec une bonne nutrition et de l'exercice peut soutenir l'IgA sécrétoire." } } ] } ] }

Sources (10000 au total)

Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway.

Neuroinflammation is one of the most important pathological processes following brain ischemia. Pulsed electromagnetic fields (PEMFs) protect against brain ischemia, but their role in regulating neuro...

Activated neutrophil-derived exosomes contribute to blood-brain barrier damage and hemorrhagic transformation after cerebral ischemia/reperfusion.

Hemorrhagic transformation (HT) caused by blood-brain barrier (BBB) damage is closely correlated with the poor prognosis of ischemic stroke. Neutrophils are proven to mediate BBB injury after ischemic... A tMCAO-HT model was constructed to assess neutrophil infiltration and its co-localization with brain microvascular endothelial cells (BMEC). After using quiet (Q-Neu) and activated neutrophil (A-Neu)... Different degrees of cerebral hemorrhage were observed in the tMCAO-HT model. The expression of the neutrophil marker Ly6G was significantly increased in tMCAO-HT model compared to the sham group, and... Neutrophils are abnormally recruited in HT after ischemic stroke, and are associated with cerebral hemorrhage. In vitro, A-Neu-derived exosomes facilitate BBB injury, which may be accomplished by exos...

Brain-targeted heptapeptide-loaded exosomes attenuated ischemia-reperfusion injury by promoting the transfer of healthy mitochondria from astrocytes to neurons.

The exchange of mitochondria reportedly plays an important role in cell-cell communication in the central nervous system (CNS). The transfer of fragmented and dysfunctional astrocytic mitochondria int... In this study, we prepared macrophage-derived exosomes laden with heptapeptide (Hep) as a dynamin-related protein-1 (Drp1)-fission 1 (Fis1) peptide inhibitor P110 to alleviate cerebral ischemia-reperf... The results demonstrated that Hep-loaded macrophage-derived exosomes (EXO-Hep) reduced mitochondrial damage in astrocytes by inhibiting the Drp1/Fis1 interaction after ischemia-reperfusion, ensuring t... EXO-Hep significantly mitigated ischemic injury in a model of transient middle cerebral artery occlusion (tMCAO) by reducing the infarct area and improving neurological performance during the process ...

Whole-brain CT Perfusion at Admission and During Delayed Time-window Detects the Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage.

To evaluate the utility of computed tomography perfusion (CTP) both at admission and during delayed cerebral ischemia time-window (DCITW) in the detection of delayed cerebral ischemia (DCI) and the ch... Eighty patients underwent CTP at admission and during DCITW. The mean and extreme values of all CTP parameters at admission and during DCITW were compared between the DCI group and non-DCI group, and ... With the exception of cerebral blood volume (P=0.295, admission; P=0.682, DCITW), there were significant differences in the mean quantitative CTP parameters between DCI and non-DCI patients both at ad... Whole-brain CTP can predict the occurrence of DCI at admission and diagnose DCI during DCITW. The extreme quantitative parameters and qualitative color-coded perfusion maps can better reflect the perf...

Leucine-Rich Alpha-2-Glycoprotein 1 is a Systemic Biomarker of Early Brain Injury and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.

After subarachnoid hemorrhage (SAH), early brain injury (EBI) and delayed cerebral ischemia (DCI) lead to poor outcomes. Discovery of biomarkers indicative of disease severity and predictive of DCI is... We performed untargeted proteomics using mass spectrometry in plasma samples collected at < 48 h of SAH in two independent discovery cohorts (n = 27 and n = 45) and identified LRG1 as a biomarker for ... Untargeted proteomics revealed higher plasma LRG1 levels across EBI severity and DCI in both discovery cohorts. In the validation cohort, the levels of LRG1 were higher in the DCI group compared with ... Plasma LRG1 is a biomarker for EBI, DCI, and functional outcomes after SAH. Further studies to elucidate the role of LRG1 in the pathophysiology of SAH are needed....

Higher Levels of Admission N-Terminal Pro-brain Natriuretic Peptide are Associated with Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage.

Delayed cerebral ischemia (DCI) greatly influences the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). We aimed to determine whether higher levels of admission N-terminal pro-bra... We retrospectively reviewed consecutive patients with aSAH between January 2018 and April 2021 in our department. Patients with admission NT-pro BNP were included for analysis. The associations betwee... A total of 415 patients with aSAH were included, among whom DCI occurred in 53 (12.8%). The admission NT-pro BNP levels were positively correlated with the cardiac troponin T levels and were significa... Higher admission levels of NT-pro BNP correlated with neurogenic cardiac injury and predicted the occurrence of DCI in patients with aSAH. A combination of the modified Fisher scale and admission NT-p...